Market Cap 238.17M
Revenue (ttm) 0.00
Net Income (ttm) -46.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,100,000
Avg Vol 1,257,254
Day's Range N/A - N/A
Shares Out 92.67M
Stochastic %K 68%
Beta 1.14
Analysts Sell
Price Target $20.00

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 689 3939
Address:
630 5th Avenue, 20th Floor, New York, United States
BioGLovesMe
BioGLovesMe Jul. 30 at 3:57 PM
$AVXL A company on the up and up doesn't miss deadlines to file basic SEC filings two quarters in a row. The zombie biotech shambles on. Dog bless.
0 · Reply
old_salt
old_salt Jul. 30 at 3:44 PM
$AVXL extremely
0 · Reply
g0eCK
g0eCK Jul. 30 at 3:22 PM
$AVXL reads like some serious homework was simply skipped by CM.
0 · Reply
rustynail59
rustynail59 Jul. 30 at 3:18 PM
$AVXL SOS different day. A lot of words on the page but no specifics. She could have cut and pasted this from the commentary on Stockwits. No mention of PDD or plans for 3-71. It took them this long to tell us this. Unbelievable!!! I’m still voting with PVG.
1 · Reply
rrogozin
rrogozin Jul. 30 at 3:13 PM
$AVXL for me the worst case scenario of fraud has been eliminated so its CM' missteps that cost him and others their jobs. A few steps back, but it seems their is a path forward along with a strong balance sheet.
1 · Reply
Itinerant
Itinerant Jul. 30 at 3:08 PM
$AVXL Her remarks do not seem to me to preclude the possibilities of seeking a conditional approval for Blarc for AD while executing the P3. What do you think? Is my view too optimistic?
0 · Reply
Lilac
Lilac Jul. 30 at 3:01 PM
$AVXL 😊
0 · Reply
PartyNaked
PartyNaked Jul. 30 at 2:35 PM
0 · Reply
ItsThrillhouse
ItsThrillhouse Jul. 30 at 2:29 PM
$AVXL "I have spent nearly three decades building and leading clinical and regulatory functions in drug development, and I’m bringing that experience to bear every day as we implement a disciplined regulatory strategy and build the right foundation for our programs." To me, adding this first person element to the PR sounds like she has heard all the commentary labeling her as a nothingburger, including the various disparagements from PVG, and wanted to make clear that we should underestimate her at our peril.
2 · Reply
g0eCK
g0eCK Jul. 30 at 2:18 PM
$AVXL Why is this not released per homepage? Or did I overlook something?
1 · Reply
Latest News on AVXL
Anavex Life Sciences Proxy statement: Proxy filing

Jul 24, 2026, 8:00 AM EDT - 6 days ago

Anavex Life Sciences Proxy statement: Proxy filing


Anavex receives expected Nasdaq delinquency notification

2026-05-22T12:13:00.000Z - 2 months ago

Anavex receives expected Nasdaq delinquency notification


Anavex delays 10Q filing

2026-05-11T23:30:42.000Z - 2 months ago

Anavex delays 10Q filing


Anavex initiated with a Buy at Rodman & Renshaw

2026-05-04T11:06:52.000Z - 3 months ago

Anavex initiated with a Buy at Rodman & Renshaw


Anavex Life Sciences Provides Comprehensive Regulatory Update

Mar 30, 2026, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Provides Comprehensive Regulatory Update


Anavex presents new data from ANAVEX2-73-AD-004 program

2026-03-23T11:45:08.000Z - 4 months ago

Anavex presents new data from ANAVEX2-73-AD-004 program


Anavex appoints Paeger to Board of Directors

2026-02-23T12:45:54.000Z - 5 months ago

Anavex appoints Paeger to Board of Directors


Anavex Life Sciences Earnings Call Transcript: Q1 2026

Feb 9, 2026, 8:30 AM EST - 6 months ago

Anavex Life Sciences Earnings Call Transcript: Q1 2026


Anavex Life Sciences Earnings release: Q1 2026

Feb 9, 2026, 8:30 AM EST - 6 months ago

Anavex Life Sciences Earnings release: Q1 2026


Anavex Life Sciences Quarterly report: Q1 2026

Feb 9, 2026, 8:30 AM EST - 6 months ago

Anavex Life Sciences Quarterly report: Q1 2026


Anavex receives FDA feedback on Alzheimer’s disease program

2026-01-06T12:36:17.000Z - 7 months ago

Anavex receives FDA feedback on Alzheimer’s disease program


Anavex Life Sciences Earnings Call Transcript: Q4 2025

Nov 25, 2025, 8:30 AM EST - 8 months ago

Anavex Life Sciences Earnings Call Transcript: Q4 2025


Anavex Life Sciences Annual report: Q4 2025

Nov 25, 2025, 8:30 AM EST - 8 months ago

Anavex Life Sciences Annual report: Q4 2025


Anavex Life Sciences Earnings release: Q4 2025

Nov 25, 2025, 8:30 AM EST - 8 months ago

Anavex Life Sciences Earnings release: Q4 2025


Anavex Life Sciences Earnings Call Transcript: Q3 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q3 2025


Anavex Life Sciences Quarterly report: Q3 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Quarterly report: Q3 2025


Anavex Life Sciences Earnings release: Q3 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings release: Q3 2025


Anavex Life Sciences Earnings Call Transcript: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q2 2025


Anavex Life Sciences Quarterly report: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Quarterly report: Q2 2025


Anavex Life Sciences Earnings release: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings release: Q2 2025


Anavex Life Sciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Proxy statement: Proxy Filing


Anavex Life Sciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Proxy statement: Proxy Filing


Anavex Life Sciences Earnings Call Transcript: Q1 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q1 2025


Anavex Life Sciences Quarterly report: Q1 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

Anavex Life Sciences Quarterly report: Q1 2025


BioGLovesMe
BioGLovesMe Jul. 30 at 3:57 PM
$AVXL A company on the up and up doesn't miss deadlines to file basic SEC filings two quarters in a row. The zombie biotech shambles on. Dog bless.
0 · Reply
old_salt
old_salt Jul. 30 at 3:44 PM
$AVXL extremely
0 · Reply
g0eCK
g0eCK Jul. 30 at 3:22 PM
$AVXL reads like some serious homework was simply skipped by CM.
0 · Reply
rustynail59
rustynail59 Jul. 30 at 3:18 PM
$AVXL SOS different day. A lot of words on the page but no specifics. She could have cut and pasted this from the commentary on Stockwits. No mention of PDD or plans for 3-71. It took them this long to tell us this. Unbelievable!!! I’m still voting with PVG.
1 · Reply
rrogozin
rrogozin Jul. 30 at 3:13 PM
$AVXL for me the worst case scenario of fraud has been eliminated so its CM' missteps that cost him and others their jobs. A few steps back, but it seems their is a path forward along with a strong balance sheet.
1 · Reply
Itinerant
Itinerant Jul. 30 at 3:08 PM
$AVXL Her remarks do not seem to me to preclude the possibilities of seeking a conditional approval for Blarc for AD while executing the P3. What do you think? Is my view too optimistic?
0 · Reply
Lilac
Lilac Jul. 30 at 3:01 PM
$AVXL 😊
0 · Reply
PartyNaked
PartyNaked Jul. 30 at 2:35 PM
0 · Reply
ItsThrillhouse
ItsThrillhouse Jul. 30 at 2:29 PM
$AVXL "I have spent nearly three decades building and leading clinical and regulatory functions in drug development, and I’m bringing that experience to bear every day as we implement a disciplined regulatory strategy and build the right foundation for our programs." To me, adding this first person element to the PR sounds like she has heard all the commentary labeling her as a nothingburger, including the various disparagements from PVG, and wanted to make clear that we should underestimate her at our peril.
2 · Reply
g0eCK
g0eCK Jul. 30 at 2:18 PM
$AVXL Why is this not released per homepage? Or did I overlook something?
1 · Reply
Sand_Pebble
Sand_Pebble Jul. 30 at 2:10 PM
$AVXL I didn’t see anything so controversial, complicated or ground breaking in that PR that it would require the extraordinary amount of time to release. It looks like a run of the mill update that they always release?
1 · Reply
Ricter61
Ricter61 Jul. 30 at 2:09 PM
$AVXL I like that CM used to say in respect to meeting with the FDA. “ you only get one chance to make a first impression “ Most likely true and his biggest FU!
0 · Reply
old_salt
old_salt Jul. 30 at 1:58 PM
0 · Reply
Logic102
Logic102 Jul. 30 at 1:56 PM
$AVXL Where are people seeing "a plan?" Why would they drop the rest of the pipeline? Rhett would seem to be low hanging fruit to get a fairly quick approval unless we were being lied to and it wasn't just a horrible trial design. I understand that AD is a huge market, but so is Parkinsons and Schizophrenia. Confusing investment to say the least. At least it's cheap here.
4 · Reply
bluespruce1
bluespruce1 Jul. 30 at 1:19 PM
$AVXL interesting timing…. Radio silence until a potential takeover. It doesn’t sound like a partnership/Buyout situation to me. Looks like attempt to go at AD alone still, dropping the other drugs. Good news is this is their plan, so we can exit now as we know this will be 5+ years out. Other ALZ drugs will certainly win the race. Not saying it can’t be taken alongside. Good to know the plan finally I guess
0 · Reply
badprecog
badprecog Jul. 30 at 12:47 PM
$AVXL Sounds like Terri might be working some magic.
3 · Reply
gogogoro
gogogoro Jul. 30 at 12:46 PM
$AVXL Them planning an ADME study is interesting and suggestive of them pursuing blar for AD because i think i remember the CHMP report mentioning the lack of an ADME study as a limitation.
1 · Reply
NorvaK
NorvaK Jul. 30 at 12:31 PM
$AVXL LOL, after 10 years avoiding the FDA!!! “Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease”
0 · Reply
focafoca99
focafoca99 Jul. 30 at 12:30 PM
$AVXL issues preliminary Q2 2026 results in a press release. https://www.rapidticker.com/news/avxl-sec-filing-f7156b
0 · Reply
coinspitter
coinspitter Jul. 30 at 12:28 PM
$AVXL Not much, but at least PD is out of scope for now, maybe they can sell Blarca for this indication?
1 · Reply
rrogozin
rrogozin Jul. 30 at 12:25 PM
$AVXL finally, good update. Sign of relief here.
0 · Reply
Georgejj
Georgejj Jul. 30 at 12:24 PM
$AVXL NEWS FROM ANAVEX LIFE SCIENCES https://www.globenewswire.com/news-release/2026/07/30/3336004/29248/en/anavex-life-sciences-reports-preliminary-second-quarter-2026-financial-results-and-provides-business-update.html?_gl=1*1qwm8ou*_up*MQ..*_ga*MTA1MjkwODQyNy4xNzg1NDEzNzk1*_ga_B6167QB2TF*czE3ODU0MTM3OTQkbzEkZzAkdDE3ODU0MTM3OTQkajYwJGwwJGg1MzcyMjg5NTU.*_ga_ERWPGTJ5X8*czE3ODU0MTM3OTQkbzEkZzAkdDE3ODU0MTM3OTQkajYwJGwwJGgw Good luck and GOD bless,
1 · Reply